Results for immunokompromessi translation from Maltese to English

tfal immunokompromessi
immunocompromised children

individwi immunokompromessi
immunocompromised

individwi immunokompromessi (ara sezzjoni 4.3)
immunocompromised individuals (see section 4.3)

imlygic ma ġiex studjat fuq pazjenti immunokompromessi.
imlygic has not been studied in immunocompromised patients.

< 1000 ċellula/mm3) jew pazjenti immunokompromessi severament.
<1,000 cells/mm3) or severely immunocompromised patients.

<1,000 ċellula/mm3) jew pazjenti immunokompromessi severament.
<1,000 cells/mm3) or severely immunocompromised patients.

individwi immunokompromessi u immunodipressi m’ għandhomx jitħallew jiġġestixxu dan il- vaċċin.
in the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.

użu f’pazjenti immunokompromessi u/jew f’pazjenti b’kondizzjonijiet awtoimmuni
use in immunocompromised patients and/or in patients with autoimmune conditions

persuni mlaqqmin immunokompromessi (eż. pazjenti b’ dijaliżi, pazjenti bi trapjanti)
immunocompromised vaccinees (e. g. dialysis patients, transplant patients)

ma teżisti ebda esperjenza klinika dwar l-użu tal-krema imiquimod għal pazjenti immunokompromessi.
no clinical experience exists with the use of imiquimod cream in immunocompromised patients.

suġġetti immunokompromessi it- tilqima ma ġietx studjata f' suġġetti b' immunità dgħajfa.
immunocompromised subjects the vaccine has not been studied in subjects with impaired immunity.

oħrajn individwi magħrufin li huma nfettati bl- hiv u li m’ humiex immunokompromessi jistgħu jiġu imlaqqma.
15 other individuals who are known to be infected with human immunodeficiency viruses and are not immunocompromised may be vaccinated.

pazjenti immunokompromessi u tfal żgħar huma f’riskju akbar li jiżviluppaw virus reżistenti għal oseltamivir waqt il-kura.
immunocompromised patients and young children are at a higher risk of developing oseltamivir-resistant virus during treatment.

informazzjoni dwar ir-riskju ta’ infezzjoni erpetika mifruxa f’pazjenti immunokompromessi ttrattati b’imlygic
information on the risk of disseminated herpetic infection in immunocompromised individuals treated by imlygic

f’individwi immunokompromessi, il-vaċċinazzjoni tista’ ma tirriżultax f’rispons protettiv xieraq minn antikorpi.
in immunocompromised individuals, vaccination may not result in an appropriate protective antibody response.

il-pazjenti immunokompromessi u l-pazjenti li jkunu qegħdin jieħdu kura immunosuppressiva sistemika ġew esklużi mill-provi kliniċi kkontrollati.
immunocompromised patients and patients taking systemic immunosuppressive therapy were excluded from controlled clinical trials.

il-pazjenti kienu immunokompromessi b’kundizzjonijiet sottostanti li kienu jinkludu tumuri malinni ematoloġiċi, newropenija wara kimoterapija, gvhd, u wara hsct.
patients were immunocompromised with underlying conditions including haematological malignancy, neutropenia post-chemotherapy, gvhd, and post hsct.

dawk li jingħataw it-tilqima għandhom jiġu infurmati li fluenz hu tilqima ta’ virus ħaj attenwat u għandu l-potenzjal għal trasmissjoni lil kuntatti immunokompromessi.
vaccine recipients should be informed that fluenz is an attenuated live virus vaccine and has the potential for transmission to immunocompromised contacts.

wara r- rikostituzzjoni tas- sistema immuni f’ pazjenti immunokompromessi b’ pml, kien osservat stabilizzazzjoni jew titjib fir- riżultat.
32 following reconstitution of the immune system in immunocompromised patients with pml, stabilisation or improved outcome has been seen.

pazjenti li għandhom riskju akbar ta’ infezzjonijiet opportunistiċi, fosthom pazjenti immunokompromessi (fosthom dawk li bħalissa qed jirċievu terapiji immunosuppressivi jew dawk immunokompromessi minħabba terapija mgħoddija).
patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies).